<DOC>
	<DOCNO>NCT02433834</DOCNO>
	<brief_summary>A Randomized , Double-Blind , Chronic Dosing ( 14 day ) , 5-Period , 7-Treatment , Placebo-Controlled , Incomplete Block , Cross-Over , Multi-center , Dose-ranging Study Assess Efficacy Safety Glycopyrronium MDI ( PT001 ) Relative Placebo MDI Open-Label Serevent Diskus Adult Subjects With Intermittent Asthma Mild Moderate Persistent Asthma</brief_summary>
	<brief_title>Chronic Dosing Cross-Over Study Assess Efficacy Safety Glycopyrronium ( PT001 ) Adult Subjects With Intermittent Asthma Mild Moderate Persistent Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Glycopyrrolate</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<criteria>1 . Give signed write informed consent participate 2 . Males females range age 18 70 year , inclusive , Screening ( Visit 1a ) 3 . A female eligible enter participate study : Nonchild bear potential ( ie. , physiologically incapable become pregnant , include female 2 year postmenopausal ) ; Child bear potential , negative serum pregnancy test Screening ( Visit 1a ) , agree 1 follow acceptable contraceptive method use consistently correctly ( ie. , accordance approve product label instruction physician duration study , Screening [ Visit 1a ] 14 day Visit 12 ) : Complete abstinence intercourse ; Implants levonorgestrel insert least 1 month prior study drug administration , beyond third successive year follow insertion ; Injectable progestogen administer least 1 month prior study drug administration administer 1 month follow study completion ; Oral contraceptive ( combine progestogen ) administer least one monthly cycle prior study drug administration ; Double barrier method : condom occlusive cap ( diaphragm cervical/vault cap ) plus spermicidal agent ( foam/gel/film/cream/suppository ) ; An intrauterine device insert qualified physician , publish data show high expected failure rate le 1 % per year ; Estrogenic vaginal ring ; Percutaneous contraceptive patch 4 . Asthma History : Have diagnosis intermittent asthma mild moderate persistent asthma , diagnose least 6 month prior Screening ( Visit 1a ) 5 . Reversibility : Diagnosis asthma confirm Screening ( Visits 1 2 ) demonstration reversibility bronchodilator define FEV1 increase least 12 % least 200 mL , 30 60 minute inhalation 4 puff salbutamol/albuterol ( Ventolin HFA ) 6 . Pulmonary Function : Must prebronchodilator FEV1 ≥60 % ≤90 % predict normal value Visit 1a/b Visit 2a/b 7 . Asthma Maintenance Therapy : For subject receive asthma maintenance therapy , must stable dose ICS nonICS therapy ( eg. , LTRA ) least 4 week prior Screening ( Visit 1a ) . 8 . Results clinical laboratory test conduct Screening ( Visit 1a ) must acceptable Investigator . 1 . LifeThreatening Asthma : A subject must lifethreatening asthma . Lifethreatening asthma defined history significant asthma episode ( ) require intubation associate hypercapnia , respiratory arrest , hypoxic seizure , asthma relate syncopal episode ( ) within 12 month prior Visit 1a ( Screening ) . 2 . Worsening Asthma : A subject must experience worsen asthma involve emergency department visit , hospitalization , use oral/parenteral corticosteroid within 6 week Screening ( Visit 1a ) . 3 . Seasonal ExerciseInduced Asthma Alone : Subjects seasonal exerciseinduced asthma exclude participation . 4 . Concurrent Respiratory Disease : A subject must current evidence diagnosis pneumonia , pneumothorax , atelectasis , pulmonary fibrotic disease , chronic bronchitis , emphysema , COPD , respiratory abnormality asthma . 5 . Concurrent Conditions/Diseases : A subject historical current evidence clinically significant , comorbid uncontrolled condition disease state , opinion Investigator , would put safety subject risk study participation would confound interpretation result condition/disease exacerbate study . 6 . Smoking History : Current smoker former smoker stop smoke within 6 month prior enrollment &gt; 10 pack year history cigarette , cigar , pipe smoking . Ecigarettes inhale marijuana treated manner tobacco product . 7 . Inhaled Anticholinergic Use : Subjects must use inhaled anticholinergic least 2 week prior Screening ( Visit 1a ) . 8 . Pregnant woman nurse mother 9 . Respiratory Tract Infection : Subjects respiratory tract infection within 6 week prior Screening ( Visit 1a ) . Subjects develop respiratory tract infection Screening Period must discontinue trial , permit reenroll later date ( least 6 week resolution respiratory tract infection ) . 10 . Uncontrolled Hypertension : Subjects , opinion Investigator , clinically significant uncontrolled hypertension . 11 . Liver Function : Subjects abnormal liver function test define aspartate aminotransferase ( AST ) , alanine aminotransferase ( ALT ) , alkaline phosphatase , total bilirubin ≥1.5 time upper limit normal repeat test . 12 . Renal : . Subjects symptomatic prostatic hypertrophy clinically significant opinion Investigator ( treat asymptomatic , subject eligible enrollment ) . Subjects transurethral resection prostate full resection prostate within 6 month prior Visit 1a exclude study . b . Subjects bladder neck obstruction urinary retention clinically significant opinion Investigator . c. Subjects calculate creatinine clearance ≤30 mL/minute use Chronic Kidney Disease Epidemiology Collaboration ( CKDEPI ) formula [ Levey , 2009 ] Visit 1a repeat test prior Visit 3 . Note : Subjects overactive bladder syndrome treat oral anticholinergic treatment least one month allow study . 13 . Glaucoma : Subjects diagnosis angle closure glaucoma exclude , regardless whether treat . Subjects diagnosis glaucoma ( nonangle closure ) , opinion Investigator , adequately treat also exclude . Subjects previously diagnose glaucoma intraocular pressure control medication ( ) eligible . All medication approve control intraocular pressure allow include topical ophthalmic nonselective βblockers betaxolol , carteolol , levobunolol , metipranolol , timolol . 14 . Cancer : Subjects cancer complete remission least 5 year . Note : Subjects squamous cell carcinoma basal cell carcinoma skin resect cure consider exclusionary . Subjects localized prostate cancer opinion Investigator , adequately work , clinically control , subject 's participation study would represent safety concern , eligible . 15 . Drug Allergy : Subjects history hypersensitivity lactose , milk protein , component MDI dry powder inhaler ( DPI ) 16 . Substance Abuse : Subjects know suspected history alcohol drug abuse within last 2year period prior Screening ( Visit 1a ) . 17 . Cardiac Conditions/Disease : Subjects document myocardial infarction within year Screening ( Visit 1a ) exclude . Subjects recent history acute coronary syndrome , undergone percutaneous coronary intervention coronary artery bypass graft within 3 month Screening ( Visit 1a ) exclude .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>